Business
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA approval earlier this year\n\n\nDUBLIN, Nov. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021. This includes five presentations from investigator-sponsored trials and three presentations from collaboration studies with The University of Texas MD Anderson Cancer Center (MD Anderson). \n\"The data at ASH demonstrates Jazz's focus on making a difference for people living with rare forms of leukemias and blood cancers, both through the development of new treatment options as well as further evaluating our currently approved medicines,\" said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals. \"Our support of several investigator-sponsored and collaboration trials exemplifies our commitment to working with experts to enable studies beyond our own company-sponsored trials, and to identifying new treatment options for patients through a variety of means.\" \nHighlights at ASH include:\nA poster presentation sharing, for the first time, data from the Phase 2/3 study of Rylaze in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who developed hypersensitivity or silent inactivation to a long-acting E. coli–derived asparaginase. Results for Vyxeos® (daunorubicin and cytarabine) in acute myeloid leukemia (AML) including an oral presentation from a real-world evidence study of Vyxeos use in newly diagnosed patients and a poster presentation from a Phase 1b study of lower-dose Vyxeos in combination with venetoclax in patients with AML who are unfit for intensive chemotherapy. Data for Vyxeos use in new patient populations, including oral presentations of two studies of Vyxeos as treatment in higher risk Myelodysplastic Syndrome (MDS). A poster presentation with final results from a real-world evidence study, DEFIFrance, of Defitelio® (defibrotide sodium) treatment in adults with severe or very severe veno-occlus...